Application of structured statistical analyses to identify a biomarker predictive of enhanced tralokinumab efficacy in Phase III clinical trials for severe, uncontrolled asthma

Mattis Gottlow, David J. Svensson, Ilya Lipkovich, Monika Huhn, Karin Bowen, Peter Wessman, Gene Colice

**Additional file 2**

**Parameter** **modifications applied to the SIDES algorithm**

* Removing the restriction on subgroup size (set to at least 240 participants in the primary runs)
* Adding age, region and number of previous exacerbations to the splitting criterion model used in the search algorithm
* Adding age, previous exacerbations (2 or ≥3), body mass index, previous smoking status, previous inhaled corticosteroid use (low/medium or high), region and baseline forced expiratory volume in 1 second (FEV1) to the list of candidate splitters,and allowing subgroups to be based on more than one variable
* Using % change from baseline in FEV1 and change from baseline in Asthma Control Questionnaire-6, Asthma Quality of Life Questionnaire and symptom score as outcome variables